Long-Term Stability Prediction for Developability Assessment of Biopharmaceutics Using Advanced Kinetic Modeling

被引:17
作者
Evers, Andreas [1 ]
Clenet, Didier [2 ]
Pfeiffer-Marek, Stefania [3 ]
机构
[1] Merck Healthcare KGaA, Discovery Technol, Global Res & Dev, D-64293 Darmstadt, Germany
[2] Sanofi Pasteur, Bioproc R&D Dept, F-69280 Marcy Letoile, France
[3] Sanofi Aventis Deutschland GmbH, Global CMC Dev, Ind Pk Hoechst, D-65926 Frankfurt, Germany
关键词
shelf life prediction; advanced kinetic analysis; chemical stability; physico-chemical properties; developability; formulation; in silico modeling; peptides; biologics; STORAGE-CONDITIONS; THERMAL-STABILITY; AGGREGATION; FORMULATION; PHARMACEUTICALS; SELECTION; PRODUCTS; DELIVERY;
D O I
10.3390/pharmaceutics14020375
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A crucial aspect of pharmaceutical development is the demonstration of long-term stability of the drug product. Biopharmaceuticals, such as proteins or peptides in liquid formulation, are typically administered via parental routes and should be stable over the shelf life, which generally includes a storing period (e.g., two years at 5 degrees C) and optionally an in-use period (e.g., 28 days at 30 degrees C). Herein, we present a case study where chemical degradation of SAR441255, a therapeutic peptide, in different formulations in combination with primary packaging materials was analyzed under accelerated conditions to derive long-term stability predictions for the recommended storing conditions (two years at 5 degrees C plus 28 days at 30 degrees C) using advanced kinetic modeling. These predictions served as a crucial decision parameter for the entry into clinical development. Comparison with analytical data measured under long-term conditions during the subsequent development phase demonstrated a high prediction accuracy. These predictions provided stability insights within weeks that would otherwise take years using measurements under long-term stability conditions only. To our knowledge, such in silico studies on stability predictions of a therapeutic peptide using accelerated chemical degradation data and advanced kinetic modeling with comparisons to subsequently measured real-life long-term stability data have not been described in literature before.
引用
收藏
页数:17
相关论文
共 52 条
[1]   Predicting Antibody Developability Profiles Through Early Stage Discovery Screening [J].
Bailly, Marc ;
Mieczkowski, Carl ;
Juan, Veronica ;
Metwally, Essam ;
Tomazela, Daniela ;
Baker, Jeanne ;
Uchida, Makiko ;
Kofman, Ester ;
Raoufi, Fahimeh ;
Motlagh, Soha ;
Yu, Yao ;
Park, Jihea ;
Raghava, Smita ;
Welsh, John ;
Rauscher, Michael ;
Raghunathan, Gopalan ;
Hsieh, Mark ;
Chen, Yi-Ling ;
Nguyen, Hang Thu ;
Nguyen, Nhung ;
Cipriano, Dan ;
Fayadat-Dilman, Laurence .
MABS, 2020, 12 (01)
[2]   Physicochemical and Formulation Developability Assessment for Therapeutic Peptide Delivery-A Primer [J].
Bak, Annette ;
Leung, Dennis ;
Barrett, Stephanie E. ;
Forster, Seth ;
Minnihan, Ellen C. ;
Leithead, Andrew W. ;
Cunningham, James ;
Toussaint, Nathalie ;
Crocker, Louis S. .
AAPS JOURNAL, 2015, 17 (01) :144-155
[3]  
Bhuyian H., 2015, EUR J BIOMED PHARM S, V2, P30
[4]   Physicochemical Principles of Protein Aggregation [J].
Bolognesi, Benedetta ;
Gaetano Tartaglia, Gian .
OLIGOMERIZATION IN HEALTH AND DISEASE, 2013, 117 :53-72
[5]   Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist [J].
Bossart, Martin ;
Wagner, Michael ;
Elvert, Ralf ;
Evers, Andreas ;
Hubschle, Thomas ;
Kloeckener, Tim ;
Lorenz, Katrin ;
Moessinger, Christine ;
Eriksson, Olof ;
Velikyan, Irina ;
Pierrou, Stefan ;
Johansson, Lars ;
Dietert, Gabriele ;
Dietz-Baum, Yasmin ;
Kissner, Thomas ;
Nowotny, Irene ;
Einig, Christine ;
Jan, Christelle ;
Rharbaoui, Faiza ;
Gassenhuber, Johann ;
Prochnow, Hans-Peter ;
Agueusop, Inoncent ;
Porksen, Niels ;
Smith, William B. ;
Nitsche, Almut ;
Konkar, Anish .
CELL METABOLISM, 2022, 34 (01) :59-+
[6]   Storage conditions for stability testing of pharmaceuticals in hot and humid regions [J].
Bott, Rubiana F. ;
Oliveira, Wanderley P. .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2007, 33 (04) :393-401
[7]   Use of Stability Modeling to Support Accelerated Vaccine Development and Supply [J].
Campa, Cristiana ;
Pronce, Thierry ;
Paludi, Marilena ;
Weusten, Jos ;
Conway, Laura ;
Savery, James ;
Richards, Christine ;
Clenet, Didier .
VACCINES, 2021, 9 (10)
[8]   Evaluating Current Practices in Shelf Life Estimation [J].
Capen, Robert ;
Christopher, David ;
Forenzo, Patrick ;
Huynh-Ba, Kim ;
LeBlond, David ;
Liu, Oscar ;
O'Neill, John ;
Patterson, Nate ;
Quinlan, Michelle ;
Rajagopalan, Radhika ;
Schwenke, James ;
Stroup, Walter .
AAPS PHARMSCITECH, 2018, 19 (02) :668-680
[9]  
Carpenter JF, 1999, METHOD ENZYMOL, V309, P236
[10]  
Clenet D, 2020, STP PHARMA PRAT J, P36